三隻松鼠(300783.SZ)擬推2021年事業合夥人持股計劃 規模不超385.1575萬股
格隆匯6月20日丨三隻松鼠(300783.SZ)發佈2021年事業合夥人持股計劃(草案),為配合公司中長期發展戰略規劃,建立和完善員工、股東的利益共享機制,公司推出該持股計劃。
該持股計劃持股規模不超過385.1575萬股,約佔草案公吿日公司股本總額的0.96%。該持股計劃受讓公司回購股票的價格為0元/股,無需持有人出資。
參加該持股計劃的對象範圍為公司(含控股子公司)的董事(不含獨立董事)、高級管理人員及核心管理層/技術/業務人員,該持股計劃初始設立時持有人總人數為22人(不含預留份額),具體參加人數、名單將根據公司遴選分配及員工實際參與情況確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.